Official title and information are available only for Plus and Premium subscribers.
Patent Granted The drugs clopidogrel (Plavix), prasugrel (Efient, Effient) and ticagrelor (Brilinta) bind to this receptor and are marketed as antiplatelet agents.[3] P2Y12 inhibitors do not change the risk of death when given to people who have had a NSTEMI. They do however increase the risk of bleeding and decrease the risk of further cardiovascular problems. Thus their routine use is of questionable value.
To see the additional information details please login and subscribe to a Plus or Premium account.
